Michael S. Isakoff

4.8k total citations · 1 hit paper
35 papers, 2.2k citations indexed

About

Michael S. Isakoff is a scholar working on Pulmonary and Respiratory Medicine, Neurology and Molecular Biology. According to data from OpenAlex, Michael S. Isakoff has authored 35 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 13 papers in Neurology and 9 papers in Molecular Biology. Recurrent topics in Michael S. Isakoff's work include Sarcoma Diagnosis and Treatment (18 papers), Neuroblastoma Research and Treatments (11 papers) and Lymphoma Diagnosis and Treatment (6 papers). Michael S. Isakoff is often cited by papers focused on Sarcoma Diagnosis and Treatment (18 papers), Neuroblastoma Research and Treatments (11 papers) and Lymphoma Diagnosis and Treatment (6 papers). Michael S. Isakoff collaborates with scholars based in United States, Belgium and Canada. Michael S. Isakoff's co-authors include Richard Görlick, Stefan Bielack, Paul S. Meltzer, Francine Blei, Seth J. Orlow, Lars M. Wagner, Damon R. Reed, Masanori Hayashi, David M. Loeb and Jill P. Mesirov and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Michael S. Isakoff

34 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Osteosarcoma: Current Treatment and a Collaborative Pathway to Success

2015 1.2k citations Michael S. Isakoff, Richard Görlick et al. Journal of Clinical Oncology profile →

Peers

Michael S. Isakoff

PRM

ONCOL

SURGE

Alexander J. Chou United States

Leo Kager Austria

Hiroshi Nanjo Japan

Stefano Serra Canada

Bruce Morland United Kingdom

Heribert Juergens Germany

Liesbeth Ferdinande Belgium

Simona Gurzu Romania

Emanuela Bonoldi Italy

Akio Sakamoto Japan

Alexander J. Chou United States

Michael S. Isakoff

931 ×1.0

1.1k ×1.6

PRM

726 ×1.2

ONCOL

503 ×0.9

241 ×0.6

SURGE

Citations per year, relative to Michael S. Isakoff Michael S. Isakoff (= 1×) peers Alexander J. Chou

Countries citing papers authored by Michael S. Isakoff

Since Specialization

Citations

This map shows the geographic impact of Michael S. Isakoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael S. Isakoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael S. Isakoff more than expected).

Fields of papers citing papers by Michael S. Isakoff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael S. Isakoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael S. Isakoff. The network helps show where Michael S. Isakoff may publish in the future.

Co-authorship network of co-authors of Michael S. Isakoff

This figure shows the co-authorship network connecting the top 25 collaborators of Michael S. Isakoff. A scholar is included among the top collaborators of Michael S. Isakoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael S. Isakoff. Michael S. Isakoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gupta, Ajay, Richard F. Riedel, Scott C. Borinstein, et al.. (2024). Consensus recommendations for systemic therapies in the management of relapsed Ewing sarcoma: A report from the National Ewing Sarcoma Tumor Board. Cancer. 130(23). 4028–4039. 2 indexed citations

Reed, Damon R., Matteo Trucco, Mark Robertson‐Tessi, et al.. (2024). Pediatric Leukemia Roadmaps Are a Guide for Positive Metastatic Bone Sarcoma Trials. Journal of Clinical Oncology. 42(25). 2955–2960. 1 indexed citations

Eslin, Don, Peter E. Zage, Genevieve Bergendahl, et al.. (2023). A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma. International Journal of Cancer. 153(5). 1026–1034. 5 indexed citations

Oesterheld, Javier, William S. Ferguson, Jacqueline M. Kraveka, et al.. (2023). Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score–Matched Survival Outcome Comparisons. Journal of Clinical Oncology. 42(1). 90–102. 28 indexed citations

Gupta, Ajay, Richard F. Riedel, Chirag Shah, et al.. (2023). Consensus recommendations in the management of Ewing sarcoma from the National Ewing Sarcoma Tumor Board. Cancer. 129(21). 3363–3371. 6 indexed citations

Weiss, Aaron R., Safia K. Ahmed, Wendy Allen‐Rhoades, et al.. (2023). Joint Adult and Pediatric Working Group as a Successful Platform to Strengthen Adolescent and Young Adult (AYA) Clinical Trial Collaboration: A Report from the NCTN/SARC AYA Clinical Trials Sarcoma Working Group. Journal of Adolescent and Young Adult Oncology. 12(5). 792–793. 1 indexed citations

Hingorani, Pooja, Mark Krailo, Allen Buxton, et al.. (2022). Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group. European Journal of Cancer. 172. 264–275. 23 indexed citations

Sholler, Giselle L. Saulnier, Dan G. Duda, Genevieve Bergendahl, et al.. (2022). A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma. Clinical Cancer Research. 28(18). 3950–3957. 11 indexed citations

Oesterheld, Javier, Genevieve Bergendahl, Donald A. Berry, et al.. (2022). Matched external control analysis of event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance.. Journal of Clinical Oncology. 40(16_suppl). 10010–10010. 1 indexed citations

10.

Oesterheld, Javier, Damon R. Reed, Bhuvana A. Setty, et al.. (2020). Phase II trial of gemcitabine and nab‐paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation. Pediatric Blood & Cancer. 67(7). e28370–e28370. 16 indexed citations

11.

Reed, Damon R., Brooke L. Fridley, Masanori Hayashi, et al.. (2020). An evolutionary framework for treating pediatric sarcomas. Cancer. 126(11). 2577–2587. 31 indexed citations

12.

Isakoff, Michael S., Robert E. Goldsby, Doojduen Villaluna, et al.. (2018). A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group. Pediatric Blood & Cancer. 66(2). e27524–e27524. 17 indexed citations

13.

Isakoff, Michael S., et al.. (2016). Challenges faced in the treatment of acute lymphoblastic leukemia in adolescents and young adults. 11–11. 2 indexed citations

14.

Goldsby, Robert E., Timothy M. Fan, Doojduen Villaluna, et al.. (2013). Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: A report from the Children’s Oncology Group. European Journal of Cancer. 49(10). 2384–2391. 53 indexed citations

15.

Isakoff, Michael S., Donald A. Barkauskas, David H. Ebb, Carol D. Morris, & Douglas Letson. (2012). Poor Survival for Osteosarcoma of the Pelvis: A Report from the Children’s Oncology Group. Clinical Orthopaedics and Related Research. 470(7). 2007–2013. 37 indexed citations

16.

Hijiya, Nobuko, Blythe Thomson, Michael S. Isakoff, et al.. (2011). Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 118(23). 6043–6049. 89 indexed citations

17.

Isakoff, Michael S., et al.. (2008). A Single-Institution Experience With Treatment of Severe Acute Chest Syndrome: Lack of Rebound Pain With Dexamethasone Plus Transfusion Therapy. Journal of Pediatric Hematology/Oncology. 30(4). 322–325. 19 indexed citations

18.

Ferrer, Fernando, Michael S. Isakoff, & Martin A. Koyle. (2006). Bladder/Prostate Rhabdomyosarcoma: Past, Present and Future. The Journal of Urology. 176(4). 1283–1291. 43 indexed citations

19.

Blei, Francine, Michael S. Isakoff, & G Deb. (1997). The Response of Parotid Hemangiomas to the Use of Systemic Interferon Alfa-2a or Corticosteroids. Archives of Otolaryngology - Head and Neck Surgery. 123(8). 841–844. 27 indexed citations

20.

Orlow, Seth J., Michael S. Isakoff, & Francine Blei. (1997). Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a “beard” distribution. The Journal of Pediatrics. 131(4). 643–646. 183 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact